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The use of drugs counteracting activation of the renin-
angiotensin-aldosterone system (RAAS), such as angiotensin-
converting enzyme inhibitors (ACEi), angiotensin receptor block-
ers (ARBs), and beta-blockers, reduces morbidity and mortality in
heart failure (HF) (1). However, ACEi/ARBs and beta-blockers
do not uniformly suppress the RAAS. A long-term increase of
aldosterone, a final product of the RAAS, has been observed in up
to 40% of treated HF patients (aldosterone escape or break-
through phenomenon) (2). Aldosterone elevation, through
AAS activation, is also elicited by the frequent use of loop
iuretics, which does not improve outcome in HF (3).
Aldosterone acts on epithelial and nonepithelial cells via
he mineralocorticoid receptor (MR) or the nongenomic
athway. In the clinical setting of HF, it promotes sodium
etention, extracellular volume expansion, vasoconstriction,
nflammation, and fibrosis leading to cardiovascular and
enal injury (4).
See page 1958
The aldosterone breakthrough phenomenon (2) provides
the rationale for explaining the benefit on mortality ob-
served in 1999 using spironolactone in patients with ad-
vanced HF (RALES [Randomized Aldactone Evaluation
Study]), in combination with ACEi (5). Fourteen years
later, the EPHESUS (Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival Study) dem-
onstrated that supplementing standard medical therapy with
selective MR blocker eplerenone in patients with acute
myocardial infarction and systolic HF leads to a significant
reduction in cardiovascular death, sudden death, and hos-
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paper to disclose.pitalization for HF (6). This effect is present 30 days after
randomization (7), and occurs only with early eplerenone
administration (3 to 7 days after infarction) (8).
As compared with spironolactone, eplerenone shows a
better affinity for MR, a more consistent inhibition of
nongenomic effects of aldosterone, and a 100- to 1,000-fold
lower affinity for corticosteroids, androgen, estrogen, and
progesterone receptors (9,10).
The paper by Rossignol et al. (11), published in this issue
of the Journal, tests the hypothesis that a diuretic effect of
eplerenone might be associated with a favorable influence
on prognosis. The authors performed a retrospective anal-
ysis of the EPHESUS database on a total of 6,080 patients
of the original 6,632, excluding 261 patients who had died
during the first month of follow-up (107 in the eplerenone,
and 154 in the placebo subgroups) and 291 patients for lack
of data.
In the eplerenone group, the diuretic-like and potassium-
sparing effects were found to be present 1 month after
infarction, more pronounced, as compared with the placebo
group, and independently associated with better outcomes.
Eplerenone’s beneficial effects on prognosis were indepen-
dent from early potassium-sparing or diuretic effects. As
underscored by the authors, for the first time, a positive
prognostic influence is advocated for the “initial and short-
term” diuretic effect of a drug in patients with HF and left
ventricular systolic dysfunction complicating myocardial
infarction.
The retrospective nature of the investigation explains the
choice of estimating the diuretic effect using rough, indirect
measures, instead of using techniques directly measuring
total body water content. The authors define the diuretic
effect of eplerenone as a reduction in body weight (an
indirect measure of total body water), an increase in plasma
proteins, and a decrease in estimated plasma volume (using
a formula, applied for the first time in the HF setting).
Although there is not a strong pharmacological basis for
expecting a diuretic effect of eplerenone at the dosage used
(as confirmed by the authors themselves in the preliminary
paper to the EPHESUS study, “a 50 mg daily dose of
eplerenone is expected to be sub-hemodynamic and sub-
diuretic”) (12), all these changes were effectively observed
with a higher (not specified) magnitude in the eplerenone
group. However, no correlation was observed between body
weight and estimated plasma volume variations.
Changes in estimated plasma volume were independently
associated, on the whole population, with a benefit on the
composite endpoint of all-cause death and cardiovascular
death or cardiovascular hospitalization, as well as hospital-
ization for HF, but not on sudden death (11).
Other factors beyond eplerenone could influence the
reduction in estimated plasma volume, as well as in body
weight (1 kg at month 1), such as changes in dietary
habits, amelioration of hemodynamics, and the action of
ACEi, ARBs, and beta-blockers, which all act to antagonize
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Eplerenone 1 Month After Infarction November 1, 2011:1967–9salt and water retention. These elements could contribute to
the sustained decrease in estimated plasma volume observed
after 3 months, even more evident in the placebo than in the
eplerenone subset.
The advocated potassium-sparing effect (0.2 mEq/l at
month 1), calculated in the entire population, was indepen-
dently associated with benefit on all-cause, cardiovascular, and
sudden death (11). Again, one should consider that factors
other than eplerenone (e.g., ACEi, ARBs use, potassium
supplementation, and possible sparing of loop diuretics dose)
might contribute to prevent potassium oscillations.
Finally, in this subset of the original cohort (i.e., 1-month
survivors, with follow-up beginning 30 days after random-
ization), eplerenone still shows beneficial effects on both the
composite endpoint of cardiovascular hospitalization and
all-cause (or cardiovascular) death, and hospitalization for
HF, independent of early K-sparing or diuretic-like ef-
ects. Conversely, the positive prognostic impact of epler-
none on all-cause death, cardiovascular death, and sudden
ardiac death (6–8) is lost (11). This finding raises ques-
ions that remain unanswered, suggesting that the protective
ction of eplerenone could take place through different
athways for early or delayed fatal events. As previously
tated by the EPHESUS investigators, the mortality benefit
ithin the first month “is largely driven by a striking
eduction in sudden cardiac death” (6,7). This observation
uggests that the protective effect of eplerenone may be
redominantly due to its actions on early electrical remod-
ling, counteracting fatal arrhythmias (10,13). More re-
ently, eplerenone was also shown to be effective in reducing
he risk of hospitalization, and overall and cardiovascular
ortality, in chronic HF patients with ejection fraction
35% and mild symptoms (EMPHASIS [Eplerenone in
ild Patients Hospitalization and Survival Study in Heart
ailure]); however, it did not reduce the risk of sudden
eath (14). All in all, these findings suggest that the
bserved “antiarrhythmic” effect of eplerenone during the
ubacute phase of infarction might be lost in chronic HF.
onversely, the observed benefit in 1-month survivors,
estricted to hospitalization for HF and the composite of
eath and hospitalization, is more likely to be associated
ith the pleiotropic actions of eplerenone in nonepithelial
issues, which prevent cardiovascular remodeling, disease
rogression, and systemic involvement (15). To further
larify this, a comparative analysis of patients’ characteristics
nd mode of death between 1-month survivors and patients
ffected by premature death is required.
Alternatively, the attenuation of the protective effect of
plerenone on mortality in 1-month survivors could be
xplained by the observation that mineralocorticoid receptor
lockade increases the aldosterone level in HF through
ositive feedback (16), underscoring that initial drug efficacy
ight be blunted by maladaptive neurohormonal mecha-
isms. As a future perspective, further studying the aldoste-
one breakthrough phenomenon in HF patients could allow
linicians to identify subsets with incomplete neurohor-onal drug antagonism and worse prognosis, though on
ptimal treatment (17). This could permit optimizing the
dministration of aldosterone receptor blockers, as well as
upplementing current treatment with novel drugs that
lunt aldosterone secretion, such as direct renin inhibitors
18) or aldosterone-synthase inhibitors (19).
As concerns the intriguing observation of a benefit on
ardiovascular outcomes of a diuretic-like effect of low-dose
plerenone in patients with HF complicating myocardial
nfarction, prospective studies are indicated, controlled for
ll potential confounders and designed to test the presence
f a diuretic effect through suitable, validated techniques,
uch as bioelectrical impedance analysis (20).
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